FDA Approves Durvalumab (Imfinzi) for Urothelial Cancer

FDA Approves Durvalumab (Imfinzi) for Urothelial CancerIt’s an accelerated approval for patients with urothelial carcinoma, which is, most commonly, a type of bladder cancer.
FDA ApprovalsIt’s an accelerated approval for patients with urothelial carcinoma, which is, most commonly, a type of bladder cancer.
FDA Approvals
Go to Source
Author:

Powered by WPeMatico